Recent discussions on X about Tenaya Therapeutics (TNYA) have centered around the company’s high-profile appearances at industry conferences, notably the Cell & Gene Meeting on the Mesa in Phoenix. Posts on the platform highlight enthusiasm for CEO Faraz Ali’s presentations and upcoming participation in the H.C. Wainwright Genetic Medicines Virtual Conference, with many users intrigued by the potential for new updates on their heart disease therapies.
Additionally, there’s buzz around insider buying activity and clinical trial progress, with some users pointing to significant investments and funding as signs of confidence in the company’s future. The conversation reflects a mix of curiosity and optimism, as participants speculate on how these developments might impact the stock’s trajectory in the near term.
Note: This discussion summary was generated from an AI condensation of post data.
Tenaya Therapeutics Insider Trading Activity
Tenaya Therapeutics insiders have traded $TNYA stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $TNYA stock by insiders over the last 6 months:
- FARAZ ALI (Chief Executive Officer) has made 0 purchases and 4 sales selling 17,722 shares for an estimated $19,621.
- WHITTEMORE TINGLEY (Chief Medical Officer) has made 0 purchases and 4 sales selling 7,990 shares for an estimated $7,631.
- TOMOHIRO HIGA (SVP, Finance) has made 0 purchases and 4 sales selling 4,352 shares for an estimated $4,326.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Tenaya Therapeutics Hedge Fund Activity
We have seen 45 institutional investors add shares of Tenaya Therapeutics stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CASDIN CAPITAL, LLC removed 6,371,002 shares (-94.6%) from their portfolio in Q2 2025, for an estimated $3,893,956
- WOODLINE PARTNERS LP removed 5,916,167 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,615,961
- BLACKROCK, INC. removed 2,523,802 shares (-48.0%) from their portfolio in Q2 2025, for an estimated $1,542,547
- JPMORGAN CHASE & CO removed 2,258,512 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,380,402
- VR ADVISER, LLC removed 1,555,556 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $950,755
- AQR CAPITAL MANAGEMENT LLC added 966,569 shares (+124.6%) to their portfolio in Q2 2025, for an estimated $590,766
- STATE STREET CORP removed 915,431 shares (-81.4%) from their portfolio in Q2 2025, for an estimated $559,511
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Tenaya Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $TNYA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/02/2025
- Chardan Capital issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for Tenaya Therapeutics, check out Quiver Quantitative's $TNYA forecast page.
Tenaya Therapeutics Price Targets
Multiple analysts have issued price targets for $TNYA recently. We have seen 2 analysts offer price targets for $TNYA in the last 6 months, with a median target of $7.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $5.0 on 09/02/2025
- Geulah Livshits from Chardan Capital set a target price of $9.0 on 08/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
